PMID- 16619518
OWN - NLM
STAT- MEDLINE
DCOM- 20060511
LR  - 20061115
IS  - 0250-7005 (Print)
IS  - 0250-7005 (Linking)
VI  - 26
IP  - 2A
DP  - 2006 Mar-Apr
TI  - Is aneusomy of chromosome 9 alone a valid biomarker for urinary bladder cancer 
      screening?
PG  - 1161-5
AB  - BACKGROUND: Detection of genetically-changed tumor cells in the urine is one of 
      the new approaches for the screening of bladder carcinomas. In a previous study, 
      numerical aberrations of chromosome 9 were found in 85.18% of bladder tumors 
      studied by the fluorescence in situ hybridization (FISH) technique. The purpose 
      of the present study was to investigate whether chromosome 9 aneusomy alone is a 
      valid, cost effective, biomarker for bladder cancer screening. MATERIALS AND 
      METHODS: Twenty-seven voided urine specimens obtained from 22 bladder cancer 
      patients, either at initial diagnosis or at the follow-up, were analyzed by the 
      FISH technique with the centromeric probe specific for chromosome 9. RESULTS: In 
      all except 2 out of the 13 specimens with a histological confirmation of cancer, 
      FISH analysis showed aneusomy 9 (sensitivity 84.61%). Among 6 cases with a 
      negative cystoscopy but a positive FISH analysis, 3 recurred within the following 
      2 months, while 2 no-recurrent patients continued to show positive FISH findings 
      after 6 months. One patient was considered to be false-positive. Four cases with 
      a negative cystoscopy showed disomy 9 and 2 of them recurred. CONCLUSION: 
      Aneusomy 9 has a high sensitivity (84.61%) for the detection of bladder cancer. 
      Patients with a negative cystoscopy but with aneusomy 9 should be kept under 
      close clinical surveillance for potential disease recurrence. However, negative 
      FISH results might not be a negative predictor for disease recurrence. Our 
      results encourage further studies with a large number of patients and a long-term 
      follow-up with concurrent FISH analysis.
FAU - Panani, Anna D
AU  - Panani AD
AD  - Critical Care Department, Medical School of Athens University, Research Unit, 
      "Evangelismos" Hospital, Athens 10676, Greece. apanani@med.uoa.gr
FAU - Kozirakis, Diomidis
AU  - Kozirakis D
FAU - Anastasiou, John
AU  - Anastasiou J
FAU - Babanaraki, Athanasia
AU  - Babanaraki A
FAU - Malovrouvas, Dimitrios
AU  - Malovrouvas D
FAU - Roussos, Charis
AU  - Roussos C
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - *Chromosome Aberrations
MH  - Chromosomes, Human, Pair 9/*genetics
MH  - Cost-Benefit Analysis
MH  - Female
MH  - Humans
MH  - In Situ Hybridization, Fluorescence/economics/methods
MH  - Male
MH  - Middle Aged
MH  - Sensitivity and Specificity
MH  - Urinary Bladder Neoplasms/diagnosis/*genetics/pathology/urine
EDAT- 2006/04/20 09:00
MHDA- 2006/05/12 09:00
CRDT- 2006/04/20 09:00
PHST- 2006/04/20 09:00 [pubmed]
PHST- 2006/05/12 09:00 [medline]
PHST- 2006/04/20 09:00 [entrez]
PST - ppublish
SO  - Anticancer Res. 2006 Mar-Apr;26(2A):1161-5.